FilingSEC EDGAR8-K
IRulya Therapeutics Receives Nasdaq Delisting Warning Due to Equity Deficiency
· SEC accepted
StageWarning
Filing content
IRulya Therapeutics received a Nasdaq delisting warning for failing to meet the $10 million minimum stockholders' equity requirement and must submit a compliance plan by October 15, 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…